Table 1.
Clinical characteristics of the iMCD cohorts
| iMCD-TAFRO, cohort 1 (N = 10) | iMCD-TAFRO, cohort 2 (N = 10) | iMCD-NOS (N = 6) | |
|---|---|---|---|
| Age, y; mean (range) | 30 (1-65) | 38 (17-67) | 46 (30-62) |
| Sex, female:male | 3:7 | 5:5 | 2:4 |
| TAFRO criteria, present/assessed | |||
| Thrombocytopenia | 10/10 | 10/10 | 0/6 |
| Anasarca or edema | 10/10 | 10/10 | 0/6 |
| Constitutional symptoms | 10/10 | 10/10 | 6/6 |
| Reticulin myelofibrosis | 7/8 | 4/5 | 3/3 |
| Renal dysfunction | 4/10 | 5/10 | 1/6 |
| Hepatomegaly and/or splenomegaly | 8/10 | 10/10 | 3/5 |
| Inflammation and organ dysfunction | |||
| CRP, mg/L | N = 7 | N = 8 | N = 3 |
| Mean (SD) | 140 (66) | 134 (123) | 89 (79) |
| IL-6/ULN | N = 7 | N = 3 | |
| Mean (SD) | 2.3 (1.29) | 7 (7) | N.A. |
| VEGF/ULN | N = 7 | N = 4 | N = 4 |
| Mean (SD) | 4 (2) | 8 (10) | 3 (4) |
| IgG, mg/dL | N = 9 | N = 7 | N = 4 |
| Mean (SD) | 1040 (571) | 1500 (820) | 3900 (2780) |
| Albumin, g/dL | N = 10 | N = 9 | N = 6 |
| Mean (SD) | 2.5 (0.5) | 2.2 (0.8) | 3.1 (0.8) |
| Creatinine, mg/dL | N = 10 | N = 10 | N = 6 |
| Mean (SD) | 1.3 (0.9) | 1.6 (1.3) | 0.9 (0.2) |
Not all symptoms and laboratory values were assessed for every patient; therefore, the ratios of symptoms present over those assessed are given for the TAFRO criteria, and the specific sample sizes are shown for each laboratory value provided.
IgG, immunoglobulin G; SD, standard deviation; ULN, upper limits of normal; VEGF, vascular endothelial growth factor.